Introduction {#s01}
============

Hematopoietic stem cell (HSC) transplantation (HSCT) is a curative treatment for many hematological, immunological, and malignant diseases. Graft failure and delayed engraftment can be caused by HLA incompatibility between donor and recipient, decreased fitness, or a low number of stem cells available for transfer ([@bib4]; [@bib8]; [@bib36]; [@bib35]). The risk factors for receiving insufficient numbers of vital cells are manifold and include relevant differences in body weight between patient and donor ([@bib58]) and umbilical cord blood (UCB) as stem cell source, because a single UCB sample contains a limited number of hematopoietic stem and progenitor cells (HSPCs) that often do not suffice to successfully reconstitute an adult patient ([@bib53]; [@bib3]). In the setting of peripheral blood stem cell transplantation, insufficient stem cell numbers might be collected from donors showing limited response to G-CSF treatment (poor mobilizers; [@bib1]).

Different approaches to provide higher vital donor stem cell numbers to the recipient are currently being investigated in preclinical studies and clinical trials ([@bib45]). For poor mobilizers, combined treatment of the donor with G-CSF and the CXCR4 antagonist plerixafor has been shown to efficiently increase the yield of stem cells ([@bib1]). To obtain higher cell numbers for UCB transplantation, two grafts can be cotransplanted ([@bib23]) or HSPCs can be expanded ex vivo before transplantation ([@bib25]). HSPC expansion, however, may come at the cost of reduced stemness, because proliferating HSPCs tend to differentiate and lose their self-renewal potential and long-term repopulating ability ([@bib11]; [@bib12]). Currently, the most promising strategy for ex vivo expansion involves the cytokines SCF, FLT3L, TPO, and IL-6 in combination with the aryl hydrocarbon receptor antagonist stemregenin-1 (SR-1; [@bib5]; [@bib54]).

We have recently shown that a substantial number of donor HSPCs are lost during transplantation because of apoptotic cell death controlled by BCL-2 family proteins and that the lack of signals derived from the stem cell niche participates in this transplantation-associated apoptosis ([@bib32]). Upon harvest or mobilization for HSCT, HSPCs are deprived of critical prosurvival signals, such as cytokines or cell--cell or cell--matrix interactions, and lack of these signals triggers apoptosis. Destruction of stem cell niches by toxic preparative conditioning regimens (e.g., total body irradiation) prolongs the period of decreased survival signals from host tissues, further priming HSPCs for apoptosis ([@bib24]).

Both cytokine deprivation and detachment from the extracellular matrix induce cell death via the intrinsic apoptosis pathway. Intrinsic apoptosis is regulated by the BCL-2 protein family, which consists of both proapoptotic proteins (e.g., BAX, BAK, BIM, PUMA, and BMF) and antiapoptotic proteins (BCL-2, BCL-XL, MCL-1, A1/BFL, BCL-W; [@bib31]). A tightly regulated interplay between the pro- and antiapoptotic Bcl-2 family members is crucial for the generation, maintenance, and function of the hematopoietic system ([@bib29]). We have previously identified BIM and BMF as two proapoptotic BCL-2 proteins from the BCL-2 homology domain 3 (BH3)--only subgroup that are decisive for most transplantation-associated apoptosis in mice [(]{.ul}[@bib32]). Both proteins have been associated with apoptosis induced by growth factor withdrawal and cell-matrix detachment ([@bib43]; [@bib10]). In mouse lineage marker--negative, Sca-1-- and c-kit--positive (LSK) cells, a population enriched in HSPCs, both *Bim* and *Bmf* were transcriptionally repressed by the cytokines SCF and Flt3L. In the absence of these cytokines, LSK cells died mainly in a BIM-dependent manner ([@bib32]). During transplantation, lack of either BIM or BMF or overexpression of one of their antagonists, BCL-2 or BCL-XL, resulted in prolonged survival of LSK cells correlating with an increased reconstitution potential as compared with wild type competitor cells. In line, less donor BM cells were required for successful engraftment when BIM was absent. Although BMF-mediated HSPC apoptosis seemed to be relevant specifically during the early engraftment period, BIM was also critical for regulating long-term hematopoiesis. Notably, WT LSK cells were gradually displaced by BIM-deficient cells over time in competitive reconstitution experiments. In vitro and in vivo fitness of human cord blood CD34^+^ cells, a population enriched in HSPCs, could be significantly improved when BIM or BMF was knocked down individually by lentiviral shRNA, indicating that transplantation-induced apoptosis is governed by conserved pathways between mice and humans ([@bib32]). These data suggested that inhibition of BIM and/or BMF in donor HSPCs could be a useful means to achieve superior transplantation outcome. Permanent apoptosis resistance, however, is associated with an increased risk of leukemogenesis and autoimmunity, and recipient mice transplanted with *Bim^−/−^* or *Bim^−/−^Bmf^−/−^* BM cells died of autoimmune kidney disease and/or lymphoma within 1 yr ([@bib33]; [@bib57]).

An alternative approach to permanent apoptosis inhibition is to limit apoptosis resistance to a time period relevant for the transplantation procedure. Likely, this strategy would also decrease the risk of undesired side effects. To provide support for this hypothesis, we transiently inhibited BIM and BMF in mouse HSPCs by overexpression of their prosurvival antagonist BCL-XL ex vivo using adenoviral vectors or protein transduction of recombinant full-length BCL-XL. Thereby, we confirm that promoting short-term apoptosis resistance during HSCT is sufficient to improve HSPC performance. At the same time, transient BCL-XL overexpression in donor cells does not cause or accelerate lymphomagenesis in the recipients. Our findings suggest that transient inhibition of apoptosis by donor HSPC manipulation ex vivo increases the fitness of these cells without elevating the risk of adverse pathology. Thus transient apoptosis inhibition represents a promising approach to reduce the risk of graft failure and improve HSCT outcome.

Results {#s02}
=======

Short-term BCL-XL overexpression transiently protects mouse LSK cells from apoptosis without impairing colony formation {#s03}
-----------------------------------------------------------------------------------------------------------------------

To test whether ectopic but transient inhibition of intrinsic apoptosis would promote HSPC fitness, we chose the antiapoptotic protein BCL-XL because of its high affinity for various proapoptotic BH3-only proteins, particularly BIM and BMF ([@bib9]). For transient gene expression, a replication-defective adenoviral backbone based on the adenovirus serotype 5 (Ad5) and previously shown to efficiently infect mouse LSK cells was used ([@bib6]). Adenoviruses do not readily integrate into the host genome but preferentially remain episomal. With every cell division, their copy number is diluted, leading to only transient gene expression in proliferating cells ([@bib37]). The human protein BCL-XL (97% identical to the mouse protein; [@bib18]) was overexpressed under control of the CMV promoter (Ad5--BCL-XL) in mouse LSK cells ([Fig. 1 A](#fig1){ref-type="fig"}). An adenovirus expressing the fluorescent protein Venus (Ad5-Venus) was used as control. When mouse LSK cells were transfected at a multiplicity of infection of 10, highest Venus expression was observed after 1--3 d with a transduction efficiency of up to 60%. Subsequently, Venus expression gradually declined and disappeared within 7--9 d upon transduction ([Fig. 1 B](#fig1){ref-type="fig"}). Adenoviral BCL-XL overexpression was confirmed by Western blot in HeLa cells and by intracellular flow cytometry in LSK cells ([Fig. 1 C](#fig1){ref-type="fig"} and Fig. S1 B). Although viral transduction reduced LSK cell viability by ∼10% when compared with untreated controls, transiently overexpressed BCL-XL robustly inhibited apoptosis induced by exogenous DNA damage caused by the topoisomerase inhibitor etoposide, confirming functionality of the transgene ([Fig. 1 D](#fig1){ref-type="fig"}). In addition, adenoviral BCL-XL overexpression protected LSK cells from cytokine deprivation--induced apoptosis, but the strength of this protective effect decreased over time, in line with transient transgene expression ([Fig. 1 E](#fig1){ref-type="fig"}). To exclude effects of adenoviral infection and/or BCL-XL overexpression on differentiation, transduced LSK cells were analyzed for their colony-forming potential, but no substantial differences were observed ([Fig. 1 F](#fig1){ref-type="fig"}).

![**Adenoviral overexpression of BCL-XL confers short-term protection to LSK cells.** (A) Adenoviral vectors for human BCL-XL expression were used. (B) WT LSK cells were transduced with Ad5-Venus viruses and cultured in the presence of cytokines (SCF, TPO, and Flt3L). Venus expression was determined by flow cytometry at the indicated time points. Bars represent means ± SEM (*n* = 3 independent experiments). (C) HeLa cells were transduced with the indicated adenoviruses, and BCL-XL protein was determined 48 h later. (D) LSK cells were either left untreated or transduced with the indicated adenoviruses and, at the same time, treated with 1 µg/ml etoposide. After 24 h, apoptosis was determined by flow cytometry. Bars represent means of three to four independent experiments ± SEM (Mann--Whitney test; P = 0.05 untreated vs. Ad5--BCL-XL and Ad5-Venus vs. Ad5--BCL-XL). (E) Adenovirally transduced cells were subjected to cytokine withdrawal, and apoptosis was determined by flow cytometry at the indicated time points. Bars represent means of four independent experiments ± SEM (Mann--Whitney test; P = 0.02 for untreated vs. Ad5--BCL-XL and Ad5-Venus vs. Ad5--BCL-XL at day 4 and 6; P = 0.04 for Ad5-Venus vs. Ad5--BCL-XL at day 8). (F) 300 LSK cells were transduced with adenoviruses or left untreated and cultured in MethoCult medium supplemented with rmSCF, rmIL-3, rhIL-6, and rhEpo. After 7 d, colonies were counted, and the colony type was determined based on morphological features. Bars represent means of *n* = 4 independent experiments ± SEM (Mann--Whitney test; P = 0.04 for M colonies).](JEM_20161721_Fig1){#fig1}

Donor stem cells transiently overexpressing BCL-XL display an engraftment advantage that is reflected by long-term chimerism in vivo {#s04}
------------------------------------------------------------------------------------------------------------------------------------

To test whether short-term inhibition of apoptosis by BCL-XL is sufficient to improve LSK cell fitness during transplantation, competitive reconstitution experiments using ex vivo adenovirally transduced LSK cells were performed. Ly5.1/Ly5.2 heterozygous recipient mice were lethally irradiated and reconstituted with a 50:50 mix of LSK cells derived from a Ly5.2^+^ donor and an isogenic Ly5.1^+^ donor. Whereas the Ly5.2^+^ LSK cells were infected ex vivo either with Ad5-Venus (group 1) or Ad5--BCL-XL (group 2) adenoviruses, Ly5.1^+^ competitor LSK cells were invariably infected with Ad5-Venus viruses ([Fig. 2 A](#fig2){ref-type="fig"}) in order to determine the effects of transient apoptosis inhibition that are independent of potential influences of adenoviral infection on HSC function. In addition, we transplanted a third cohort of recipient mice with a 50:50 mix of noninfected Ly5.2^+^ LSK cells and Ly5.1^+^ LSK cells infected with Ad5-Venus (group 3) to identify changes in HSC fitness conferred by the adenoviral infection itself. Recipients were sacrificed for analysis 10 d after transplantation. Analysis of recipient mice included LSK and myeloid cells isolated from the BM, thymocytes, and granulocytes and monocytes from the spleen ([Fig. 2, B--D](#fig2){ref-type="fig"}; and Fig. S2 A). Mature lymphocytes were excluded from the analysis because they were still entirely derived from the recipient mice at the time of analysis. As expected, no competitive advantage of Ly5.2^+^ donor cells was observed when both donor samples were transduced with Ad5-Venus (group 1). In contrast, Ly5.2^+^ LSK cells transiently overexpressing BCL-XL showed a strongly increased engraftment as reflected by displacement of Ly5.1^+^ cells (group 2). This indicates that apoptosis-resistant LSK cells had a robust competitive advantage during transplantation. The higher number of Ly5.2^+^ granulocytes and monocytes in the BM of group 2 recipient mice compared with group 1 mice reflects a faster onset of blood formation (Fig. S2 A). However, a strong predominance of Ly5.2^+^ cells over Ly5.1^+^ cells was observed in group 3 recipient mice, indicating that the adenoviral infection of HSPCs ex vivo resulted in a substantial loss in competitiveness in vivo, a result that was not anticipated from the colony-forming assays described above ([Fig. 1 F](#fig1){ref-type="fig"}). To determine whether adenoviral infection by itself is toxic in a cell-intrinsic manner or whether infected and/or Venus-overexpressing cells are eliminated by recipient T cells, competitive reconstitution experiments were performed using T cell--deficient Ly5.2^+^ *Rag1^−/−^* recipients. As described previously, engraftment of Ly5.1^+^ cells in Ly5.2^+^ recipients was generally low ([@bib55]). However, despite the absence of T cells, Ad5-Venus--infected LSK cells performed significantly worse than noninfected counterparts, indicating cell-intrinsic toxicity of adenoviral infection in mouse HSPCs as the major cause of poor engraftment (Fig. S2 B).

![**Adenoviral BCL-XL overexpression confers a stable competitive advantage during reconstitution in vivo.** (A) Lethally irradiated heterozygous Ly5.1/Ly5.2 recipient mice were competitively transplanted with Ly5.1^+^ and Ly5.2^+^ LSK cells in a 50:50 ratio, which were pretreated as indicated in the table. (B--D) 10 d after transplantation, mice were sacrificed and analyzed. The dashed bar indicates the period of adenoviral gene expression. The Ly5.1^+^/ Ly5.2^+^ chimerism was determined by flow cytometry in splenic monocytes and granulocytes (B), double-negative (DN) and double-positive (DP) thymocytes (C), and BM-derived LSK cells (D). (E--G) Another set of mice was analyzed 16 wk after transplantation. The Ly5.1^+^/ Ly5.2^+^ chimerism was determined by flow cytometry in splenic monocytes and granulocytes (E), T lymphocytes (F), and BM-derived LSK cells (G). Bars represent means of *n* = 6--8 animals of two independent experiments ± SEM. Significant p-values (Wilcoxon test; Ly5.1^+^ vs. Ly5.2^+^): (B) Group 2: P = 0.05 in monocytes; (C) Group 1: P = 0.02 for DN4; Group 2: DN4 and DP, P = 0.03 for DN2 and DN3; Group 3: P = 0.05 for DN2, P = 0.03 for DN3, DN4, and DP; (D) Group 1: P = 0.03; Group 2: P = 0.05; (E) Group 3: P = 0.01 for monocytes; (F) Group 2+3: P = 0.02 for CD4^+^ T cells; P = 0.01 for CD8^+^ T cells; (G) Group 2: P = 0.02; group 3: P = 0.01.](JEM_20161721_Fig2){#fig2}

Because apoptosis inhibition in our system is restricted to the first days after transplantation, the chimerism at day 10 should be stably transmitted to later time points. Indeed, analysis of recipient mice of all experimental groups 16 wk after transplantation showed an overall similar Ly5.1^+^/Ly5.2^+^ chimerism as compared with the day 10 analysis ([Fig. 2, E--G](#fig2){ref-type="fig"}; and [Table 1](#tbl1){ref-type="table"}). This indicates that adenoviral BCL-XL overexpression conferred sufficient protection to long-term HSCs (LT-HSCs), the cells that maintain long-term hematopoiesis ([@bib42]). At this late time point, BM chimerism was also reflected by the Ly5.1^+^/Ly5.2^+^ chimerism of lymphocytes ([Fig. 2 F](#fig2){ref-type="fig"}). Importantly, Ly5.2^+^ LSK cells transduced with Ad5--BCL-XL completely outcompeted untreated Ly5.1^+^ LSK cells in a competitive setting, indicating that transient BCL-XL overexpression was able to protect mouse HSPCs from both virus-induced and transplantation-associated apoptosis (Fig. S2 C).

###### Cellular composition and chimerism of recipient mice transplanted in a competitive manner and analyzed 16 wk later

  Parameter                          Group 1                Group 2                   Group 3                     
  ---------------------------------- --------------- ------ --------- --------------- --------- -- -------------- ------
  **BM**                                                                                                          
  Cells (×10^7^)                     5.83 ± 0.46                      6.91 ± 0.31                  8.08 ± 0.61    
  Monocytes (×10^6^)                 13.20 ± 1.13                     15.32 ± 1.49                 16.86 ± 1.30   
  Granulocytes (×10^6^)              13.68 ± 2.56                     16.55 ± 2.78                 17.56 ± 2.92   
  B220^+^IgM^−^ B cells (×10^6^)     8.49 ± 1.08                      9.56 ± 1.17                  14.75 ± 1.72   
  IgM^+^ B cells (×10^6^)            5.32 ± 2.98                      4.90 ± 2.55                  6.97 ± 3.31    
  CD4^+^ T cells (×10^6^)            1.42 ± 0.19                      1.60 ± 0.14                  1.93 ± 0.21    
  CD8^+^ T cells (×10^6^)            1.19 ± 0.15                      1.40 ± 0.12                  1.47 ± 0.23    
  Ly5.1^+^ monocytes (%)             20.08 ± 8.2     0.87             20.01 ± 8.1     0.07         9.97 ± 4.0     0.02
  Ly5.2^+^ monocytes (%)             20.85 ± 9.6                      52.95 ± 7.4                  57.55 ± 9.5    
  Ly5.1^+^ granulocytes (%)          45.08 ± 6.9     0.06             24.51 ± 5.5     0.58         17.50 ± 4.6    0.09
  Ly5.2^+^ granulocytes (%)          11.86 ± 6.4                      34.30 ± 7.0                  34.86 ± 6.8    
  Ly5.1^+^ B220^+^IgM^−^ cells (%)   27.30 ± 9.2     0.87             18.65 ± 6.7     0.04         15.98 ± 5.5    0.04
  Ly5.2^+^ B220^+^IgM^−^ cells (%)   23.01 ± 7.6                      50,51 ± 6.4                  48.36 ± 6.1    
  Ly5.1^+^ B220^+^IgM^+^ cells (%)   26.27 ± 10.1    0.87             15.61 ± 7.1     0.04         14.04 ± 5.1    0.03
  Ly5.2^+^ B220^+^IgM^+^ cells (%)   21.00 ± 7.3                      40.64 ± 5.5                  46.68 ± 5.4    
  Ly5.1^+^ CD4^+^ cells (%)          11.92 ± 3.9     0.40             10.64 ± 3.5     0.02         8.87 ± 3.2     0.03
  Ly5.2^+^ CD4^+^ cells (%)          19.05 ± 5.3                      40.98 ± 5.5                  36.25 ± 5.8    
  Ly5.1^+^ CD8^+^ cells (%)          13.94 ± 5.1     0.24             8.68 ± 2.7      0.01         5.45 ± 2.0     0.01
  Ly5.2^+^ CD8^+^ cells (%)          28.15 ± 7.5                      55.16 ± 7.5                  39.33 ± 8.1    
  **Spleen**                                                                                                      
  Cells (×10^7^)                     6.13 ± 1.30                      7.91 ± 1.12                  8.22 ± 1.50    
  Monocytes (×10^6^)                 3.08 ± 0.49                      3.55 ± 0.55                  3.65 ± 0.31    
  Granulocyte (×10^6^)               1.42 ± 0.33                      1.49 ± 0.30                  1.47 ± 0.35    
  B220^+^IgM^−^ B cells (×10^6^)     16.8 ± 5.5                       23.2 ± 5.1                   23.8 ± 5.6     
  IgM^+^ B cells (×10^6^)            17.6 ± 1.11                      20.6 ± 1.03                  26.2 ± 1.51    
  CD4^+^ T cells (×10^6^)            12.3 ± 2.3                       15.4 ± 2.7                   16.5 ± 3.1     
  CD8^+^ T cells (×10^6^)            5.70 ± 1.18                      7.04 ± 1.43                  6.52 ± 1.25    
  **Thymus**                                                                                                      
  Cells (×10^7^)                     3.76 ± 0.99                      4.43 ± 0.54                  4.44 ± 0.83    
  DN cells (×10^6^)                  1.10 ± 0.29                      1.72 ± 0.14                  1.64 ± 0.38    
  DP cells (×10^6^)                  27.4 ± 8.6                       29.4 ± 5.8                   30.2 ± 7.4     
  CD4^+^ SP cells (×10^6^)           4.62 ± 1.10                      6.10 ± 0.95                  5.69 ± 1.12    
  CD8^+^ SP cells (×10^6^)           0.99 ± 0.24                      1.52 ± 0.20                  1.56 ± 0.36    
  Ly5.1^+^ DN cells (%)              28.72 ± 10.4    0.50             15.19 ± 7.1     0.02         14.57 ± 5.7    0.03
  Ly5.2^+^ DN cells (%)              36.04 ± 8.7                      47.41 ± 6.8                  53.70 ± 7.0    
  Ly5.1^+^ DP cells (%)              41.55 ± 14.6    0.74             17.37 ± 9.2     0.05         14.82 ± 7.0    0.07
  Ly5.2^+^ DP cells (%)              29.23 ± 10.7                     58.46 ± 8.4                  57.40 ± 11.3   
  Ly5.1^+^ CD4^+^ SP cells (%)       39.55 ± 13.1    0.87             17.19 ± 7.9     0.04         19.40 ± 7.7    0.07
  Ly5.2^+^ CD4^+^ SP cells (%)       35.62 ± 11.2                     58.01 ± 7.4                  54.84 ± 10.9   
  Ly5.1^+^ CD8^+^ SP cells (%)       25.08 ± 11.0    0.24             9.70 ± 4.5      0.01         8.66 ± 3.2     0.01
  Ly5.2^+^ CD8^+^ SP cells (%)       47.69 ± 12.8                     71.70 ± 7.3                  65.93 ± 9.9    
  **Blood**                                                                                                       
  Cells (/µl)                        5,593 ± 10.21                    6,436 ± 10.81                6,584 ± 9.64   
  Monocytes (/µl)                    379 ± 71                         610 ± 153                    361 ± 42       
  Granulocytes (/µl)                 702 ± 104                        1,240 ± 358                  527 ± 96       
  B220^+^IgM^−^ B cells (/µl)        1,175 ± 363                      2,154 ± 333                  1,817 ± 279    
  IgM^+^ B cells (/µl)               60 ± 38                          44 ± 17                      62 ± 28        
  CD4^+^ T cells (/µl)               891 ± 142                        1,089 ± 144                  865 ± 91       
  CD8^+^ T cells (/µl)               526 ± 104                        641 ± 92                     475 ± 60       
  Ly5.1^+^ monocytes (%)             23.43 ± 8.8     0.87             26.47 ± 11.8    0.26         10.27 ± 4.1    0.01
  Ly5.2^+^ monocytes (%)             21.20 ± 8.0                      50.56 ± 8.0                  60.36 ± 9.9    
  Ly5.1^+^ granulocytes (%)          56.70 ± 8.9     0.04             32.54 ± 8.9     0.58         25.50 ± 7.0    0.26
  Ly5.2^+^ granulocytes (%)          15.25 ± 6.5                      38.59 ± 6.6                  42.54 ± 7.6    
  Ly5.1^+^ B220^+^IgM^−^ cells (%)   25.28 ± 9.7     0.61             20.64 ± 6.8     0.03         16.42 ± 6.8    0.03
  Ly5.2^+^ B220^+^IgM^−^ cells (%)   36.30 ± 11.3                     57.08 ± 7.0                  62.93 ± 8.0    
  Ly5.1^+^ B220^+^IgM^+^ cells (%)   38.38 ± 13.1    0.47             25.37 ± 8.5     0.22         23.39 ± 8.9    0.08
  Ly5.2^+^ B220^+^IgM^+^ cells (%)   27.41 ± 13.7                     53.97 ± 10.9                 52.57 ± 10.3   
  Ly5.1^+^ CD4^+^ cells (%)          28.06 ± 12.1    0.61             19.32 ± 6.8     0.07         17.67 ± 4.9    0.04
  Ly5.2^+^ CD4^+^ cells (%)          30.01 ± 11.4                     49.75 ± 6.4                  49.37 ± 7.2    
  Ly5.1^+^ CD8^+^ cells (%)          19.60 ± 8.3     0.40             13.16 ± 4.5     0.02         9.95 ± 3.2     0.01
  Ly5.2^+^ CD8^+^ cells (%)          31.08 ± 8.8                      52.66 ± 7.0                  46.37 ± 7.3    

The transplantation procedure and groups are defined in [Fig. 3](#fig3){ref-type="fig"}. Values represent means of *n* = 7--8 animals from three independent experiments ± SEM. Significant p-values with regard to the Ly5.1^+^/Ly5.2^+^ ratio are indicated (Wilcoxon test). DN, double negative; DP, double positive; SP, single positive.

Transient adenoviral BCL-XL overexpression has no leukemogenic potential in vivo {#s05}
--------------------------------------------------------------------------------

Although we could not find evidence of aberrantly persisting BCL-XL overexpression in the in vitro experiments depicted in [Fig. 1](#fig1){ref-type="fig"}, we thoroughly analyzed the presence of BCL-XL--overexpressing hematopoietic clones that could have been generated by constitutive expression caused by random chromosomal integration of adenoviral vectors and persist in vivo ([@bib48]). Such cells would have had the chance to displace other cells over time ([@bib32]). BM cells isolated from group 2 recipient mice 16 wk after transplantation showed no increase in BCL-XL expression ([Fig. 3 A](#fig3){ref-type="fig"}), and splenocytes showed no increased apoptotic resistance to etoposide treatment when compared with cells from group 1 and 3 animals ([Fig. 3 B](#fig3){ref-type="fig"}). Importantly, we observed no signs of lympho- or myeloproliferation in six recipient mice transplanted with Ad5--BCL-XL--transduced LSK cells that were monitored for 1 yr ([Fig. 3, C and D](#fig3){ref-type="fig"}). Cells isolated from these mice were further used for serial transplantation. Donor cells showed good engraftment, and no detectable signs of lympho- or myeloproliferation were found in secondary recipients (*n* = 9/group) within 16 wk after transplantation (not depicted).

![**Adenoviral BCL-XL overexpression has no long-term adverse effects.** (A) Recipient mice were transplanted as indicated in [Fig. 2 A](#fig2){ref-type="fig"} and sacrificed 16 wk later. Total BM cells were analyzed for their BCL-XL protein contents by Western blot. The Burkitt lymphoma cell line BL40 was used as positive control and β-actin as loading control. The legend indicates how the Ly5.2^+^ donor cells were treated before transplantation. (B) Splenic cells of recipient mice were cultured for 24 h in the presence or absence of etoposide (1 µg/ml), and specific apoptosis was determined by flow cytometry. Spleens of WT mice were used as a control. Bars represent means of *n* = 3 independent experiments ± SEM. No significant differences were observed (Mann--Whitney test). (C and D) Ly5.1^+^ recipient mice were transplanted with 15,000 Ly5.2^+^ LSK cells transduced with Ad5-Venus or Ad5--Bcl-xL. To ensure survival of the recipients, 150,000 Ly5.1^+^ BM cells were co-transplanted. Recipient mice were sacrificed 1 yr later and analyzed in detail. No signs of myelo- or lymphoproliferation or leukemia were observed in the indicated organs. Bars represent means of *n* = 6 animals ± SEM; no significant differences were observed (Mann--Whitney test). (E) LSK cells were isolated from the BM of Eμ-*myc* tg mice and left untreated or transduced with the Ad5-Venus or Ad5--BCL-XL adenoviruses. Subsequently, LSK cells were transduced into lethally irradiated recipient mice, which were monitored for lymphoma development. (F) When in poor general condition, recipient mice were sacrificed and analyzed. The Kaplan--Meier blot shows *n* = 13--18 mice per group (four independent experiments). No significant p-values between the groups were obtained by using the log-rank (Mantel--Cox) test.](JEM_20161721_Fig3){#fig3}

Stable overexpression of BCL-XL or BCL-2 is not sufficient in itself to transform hematopoietic cells ([@bib49]). In contrast, overexpression of either protein or deletion of their antagonist BIM strongly accelerates lymphomagenesis in *Eµ-MYC* transgenic mice ([@bib49]; [@bib17]). To test the oncogenic potential of transient apoptosis resistance in such a "worst case scenario," we reconstituted lethally irradiated recipients with *Eµ-MYC* transgenic LSK cells transduced with either Ad5-Venus or Ad5--BCL-XL or left untreated ([Fig. 3 E](#fig3){ref-type="fig"}). Recipient mice of all experimental groups developed lymphoma within the same time period ([Fig. 3 F](#fig3){ref-type="fig"}). In sum, these data indicate that transient BCL-XL expression in HSPCs does not lead to the accumulation of aberrant cells or accelerate lymphomagenesis on a predisposed genetic background, further documenting the safety of our approach.

Transient pan-caspase inhibition does not sufficiently protect mouse HSPCs from apoptosis in vivo {#s06}
-------------------------------------------------------------------------------------------------

As adenoviral transduction appears of limited use for therapeutic HSPC manipulation because of toxic effects, we moved on to test whether the pan-caspase inhibitor Q-VD-OPh could serve as an alternative means to block transplantation-associated apoptosis. When LSK cells were continuously treated with Q-VD-OPh in vitro, they were strongly protected from cytokine deprivation--induced apoptosis. Additional inhibition of necroptosis, an alternative type of cell death induced by certain members of the TNF family (e.g., upon viral infection), by Necrostatin-1 (Nec1) further increased cell viability (Fig. S3 A). This suggests that a fraction of the cell-autonomous death in vitro may be triggered by autocrine death receptor signaling, but its overall contribution to HSPC cell death appears minor. To test whether HSCT could benefit from transient ex vivo treatment with caspase and necroptosis inhibitors, LSK cells were initially treated with Q-VD-OPh for 24 h, followed by a period of 8 d where the cells were subjected to cytokine deprivation--induced stress in vitro. As shown in Fig. S3 B, no sustained protective effect could be observed under these conditions. Accordingly, cotransplantation of Ly5.2^+^ LSK cells treated with Q-VD-OPh (+/− Nec1) and untreated Ly5.1^+^ LSK cells into Ly5.1/Ly5.2 heterozygous recipients resulted in a similar engraftment with ∼50% Ly5.2^+^ and 50% Ly5.1^+^ progeny cells (Fig. S3, C--F). Thus, transient cell death inhibition of isolated LSK cells using a caspase and/or necroptosis inhibitor is not sufficient to promote improved engraftment.

Transient transduction of full-length BCL-XL protein protects LSK cells from apoptosis in vitro {#s07}
-----------------------------------------------------------------------------------------------

We next explored a system of nonviral delivery of BCL-XL into LSK cells. Protein transduction represents a safe alternative to viral gene transfer without the risk of genomic integration or recombination events. Cellular protein uptake is enabled by cell-penetrating peptides (CPPs) mainly composed of positively charged amino acids ([@bib44]). The protein transduction domain (PTD) from the HIV TAT protein (TAT~48--57~) was chosen as the CPP. In our first approach, we used a commercially available fusion of the TAT-PTD to the BCL-2 homology domain 4 (BH4) domain of human BCL-XL (HIV-TAT~48--57~-β-Ala--BCL-XL BH~44-23~, sequence: Ac-GRKKRRQRRR-βA-SNRELVVDFLSYKLSQKGYS-OH). The BH4 domain was shown to be relevant for the antiapoptotic function of BCL-2 and BCL-XL and to inhibit apoptosis even as an isolated domain ([@bib27]; [@bib50]). In various in vitro and in vivo mouse models, TAT-BH4 treatment resulted in protection from apoptosis ([@bib28]; [@bib26]; [@bib15]). However, despite its efficient cellular uptake and mitochondrial localization, TAT-BH4 did not confer any protection to LSK cells subjected to the cytotoxic agents Taxol and etoposide (Fig. S4, A--C).

Next, we bacterially expressed full-length mouse Bcl-xL protein coupled to the TAT-PTD (6xHis-TAT~49--57~(RKKRRQRRR)--Bcl-xL--HA) and purified it to homogeneity using metal affinity chromatography. LSK cells were incubated with 1.5 µM TAT--Bcl-xL for 2 h, and protein uptake was measured after 24 h by intracellular flow cytometry and fluorescence microscopy using an anti--Bcl-xL antibody. We observed pronounced cellular uptake ([Fig. 4 A](#fig4){ref-type="fig"}) and mitochondrial as well as cytoplasmic localization of the protein ([Fig. 4 B](#fig4){ref-type="fig"}). To verify correct localization by a different method, we transduced HeLa cells with TAT--Bcl-xL and harvested cells at different time points. Fractionated Western blotting analysis was performed 24 h after transduction and confirmed the localization of TAT--Bcl-xL to the cytosol and mitochondria (Fig. S5 A), mimicking the localization of the endogenous protein ([@bib16]). Time kinetics revealed a rapid decrease of TAT--Bcl-xL protein within the first 24 h upon uptake with the appearance of a shorter fragment, indicating protein degradation (Fig. S5 B). Occurrence of the short protein fragment could not be prevented by proteasome inhibition using MG132, indicating that the protein was, at least in part, degraded in a nonproteasomal manner (Fig. S5 C), most likely in lysosomes. Functional assays showed that TAT--Bcl-xL protein transduction resulted in a robust protection of LSK cells from apoptosis induced by etoposide or cytokine deprivation for 6--8 d ([Fig. 4, C and D](#fig4){ref-type="fig"}). During this time period, TAT--Bcl-xL protein content decreased gradually and more rapidly in proliferating cells ([Fig. 4 E](#fig4){ref-type="fig"}). Hence, we show here that recombinant TAT--Bcl-xL transiently and efficiently protects LSK cells from stress-induced apoptosis in vitro.

![**TAT--Bcl-xL protein is efficiently taken up by LSK cells and inhibits apoptosis**. (A) WT LSK cells were treated with dextran sulfate for 30 min and TAT--Bcl-xL for 2 h (1.5 µM). Protein content was determined 48 h later by flow cytometry using an anti--Bcl-xL antibody. (B) Localization of TAT--Bcl-xL protein in LSK cells was determined 24 h after protein transduction by fluorescence microscopy and shows TAT--Bcl-xL on mitochondria and in the cytoplasm. Bars, 5 µm. (C and D) LSK cells transduced with TAT--Bcl-xL protein were subjected to 1 µg/ml etoposide (C) or cytokine withdrawal (D). Specific apoptosis was determined by flow cytometry at indicated time points. Bars represent means of *n* = 4 independent experiments ± SEM. Significant p-values (Mann--Whitney test): (C) Untreated vs. TAT--Bcl-xL: P = 0.005 on day 2 and P = 0.01 at day 4 and 6; Buffer vs. TAT--Bcl-xL: P = 0.02 at day 2, 4, and 6; (D) Untreated vs. TAT--Bcl-xL: P = 0.005 at day 2 and 8, P = 0.01 at day 4, P = 0.02 at day 6; Buffer vs. TAT--Bcl-xL: P = 0.02 at day 2, P = 0.03 at day 4 and 6. (E) TAT--Bcl-xL--treated LSK cells were cultured in the presence or absence of cytokines. At the indicated time points, TAT--Bcl-xL--positive cells were determined by intracellular flow cytometry. Bars represent means of *n* = 4 independent experiments ± SEM.](JEM_20161721_Fig4){#fig4}

Protein transduction of full-length Bcl-xL increases LSK cell fitness in vivo {#s08}
-----------------------------------------------------------------------------

Increased resistance to apoptosis should confer competitive advantages to cells, particularly under conditions of stress. To investigate the effects of TAT--Bcl-xL on HSPC competitiveness, we transduced LSK cells isolated from Ly5.1^+^ or Ly5.2^+^ mice with TAT--Bcl-xL and co-cultured these cells with untreated LSK cells in a 50:50 ratio. Even under optimal culture conditions (i.e., media supplemented with 10% serum and the cytokines Flt3L, SCF, and TPO), TAT--Bcl-xL transduction conferred a competitive advantage, indicating that apoptosis took place during expansion ([Fig. 5 A](#fig5){ref-type="fig"}). Upon cytokine deprivation or treatment with etoposide, the Ly5.1/Ly5.2 ratio was strongly biased in favor of TAT--Bcl-xL--treated cells, demonstrating a strong protective effect during stress-induced apoptosis ([Fig. 5, B and C](#fig5){ref-type="fig"}). Encouraged by this finding, we performed competitive reconstitution experiments in mice using Ly5.2^+^ cells incubated with TAT--Bcl-xL for 2 h prior transplantation and Ly5.1^+^ competitor cells left untreated (50:50 ratio; [Fig. 5 D](#fig5){ref-type="fig"}). 16 wk after transplantation, the ratio was found shifted strongly in favor of TAT--Bcl-xL--treated Ly5.2^+^ cells (group 2; [Fig. 5, E--G](#fig5){ref-type="fig"}; and [Table 2](#tbl2){ref-type="table"}). Altogether, we have shown that recombinant Bcl-xL introduced prior transplantation and transiently expressed for 6--8 d confers substantial fitness to mouse HSPCs, leading to a competitive advantage and a superior transplantation outcome.

![**TAT--Bcl-xL protein transduction increases competitiveness of LSK cells in vitro and in vivo.** (A--C) Ly5.1^+^ and Ly5.2^+^ LSK cells were cultured in a 50:50 ratio under different culture conditions. Cells were either pretreated with TAT--Bcl-xL or left untreated and cultured for 5 d under optimal culture conditions (10% serum with SCF, TPO, and Flt3L, 100 ng/ml each; A), in the absence of cytokines (B), or in the presence of etoposide (C). Bars represent means of *n* = 4 independent experiments ± SEM. Significant p-values (Wilcoxon Test): P = 0.04 in A--C. (D) Ly5.2^+^ LSK cells treated either with TAT--Bcl-xL or left untreated were co-transplanted with untreated Ly5.1^+^ cells in a 50:50 ratio into lethally irradiated Ly5.1/Ly5.2 heterozygous mice. 16 wk later, recipient mice were sacrificed, and donor chimerism was determined by flow cytometry. The dashed bar indicates the period, in which Ly5.2^+^ LSK cells were containing TAT--Bcl-xL. (E--G) Chimerism was detected in splenic monocytes and B and T lymphocytes (E and F), as well as in BM-derived LSK cells (G). Bars represent means ± SEM of *n* = 10--11 mice from three independent experiments. Significant p-values (Wilcoxon test): (E) P = 0.02 for Group 2 in monocytes; (F) P = 0.03 for Group 2 in immature and mature B cells; (G) P = 0.03 for Group 2 in LSK cells.](JEM_20161721_Fig5){#fig5}

###### Cellular composition and chimerism of recipient mice transplanted in a competitive manner and analyzed 16 wk later

  Parameter                          Group 1                Group 2                   
  ---------------------------------- --------------- ------ --------- --------------- -------
  **BM**                                                                              
  Cells (×10^7^)                     3.58 ± 0.48                      3.83 ± 3.22     
  Monocytes (×10^6^)                 4.88 ± 1.05                      4.64 ± 0.79     
  Granulocytes (×10^6^)              10.4 ± 1.9                       1,000 ± 110     
  B220^+^IgM^−^ B cells (×10^6^)     2.86 ± 0.46                      3.81 ± 0.34     
  IgM^+^ B cells (×10^6^)            2.21 ± 0.42                      2.60 ± 0.34     
  CD4^+^ T cells (×10^6^)            0.34 ± 0.05                      0.47 ± 0.05     
  CD8^+^ T cells (×10^6^)            0.62 ± 0.09                      0.71 ± 0.10     
  Ly5.1^+^ monocytes (%)             29.64 ± 7.65    0.28             20.93 ± 8.50    0.03
  Ly5.2^+^ monocytes (%)             44.25 ± 8.85                     63.32 ± 10.70   
  Ly5.1^+^ granulocytes (%)          33.32 ± 6.20    0.65             21.24 ± 7.35    0.05
  Ly5.2^+^ granulocytes (%)          40.24 ± 8.13                     59.29 ± 11.03   
  Ly5.1^+^ B220^+^IgM^−^ cells (%)   36.26 ± 6.41    0.80             14.37 ± 6.78    0.02
  Ly5.2^+^ B220^+^IgM^−^ cells (%)   35.87 ± 7.59                     63.61 ± 8.45    
  Ly5.1^+^ B220^+^IgM^+^ cells (%)   44.41 ± 5.10    0.58             17.40 ± 7.41    0.04
  Ly5.2^+^ B220^+^IgM^+^ cells (%)   33.87 ± 5.89                     64.61 ± 7.72    
  Ly5.1^+^ CD4^+^ cells (%)          22.79 ± 2.95    0.72             10.81 ± 2.75    0.006
  Ly5.2^+^ CD4^+^ cells (%)          21.77 ± 3.64                     38.55 ± 3.83    
  Ly5.1^+^ CD8^+^ cells (%)          31.45 ± 2.43    0.01             16.40 ± 4.34    0.11
  Ly5.2^+^ CD8^+^ cells (%)          16.21 ± 2.17                     31.01 ± 3.98    
  **Spleen**                                                                          
  Cells (×10^7^)                     11.70 ± 0.86                     12.29 ± 0.73    
  Monocytes (×10^6^)                 4.36 ± 0.85                      2.88 ± 0.38     
  Granulocytes (×10^6^)              2.68±0.43                        1.76±0.25       
  B220^+^IgM^−^ B cells (×10^6^)     30.5±9.3                         35.2±7.1        
  IgM^+^ B cells (×10^6^)            37.7 ± 6.1                       39.2±6.4        
  CD4^+^ T cells (×10^6^)            19.7 ± 2.0                       19.3±1.6        
  CD8^+^ T cells (×10^6^)            9.89 ± 0.69                      9.27±0.62       
  **Thymus**                                                                          
  Cells (×10^7^)                     6.86 ± 0.84                      4.64 ± 0.86     
  DN cells (×10^6^)                  1.86 ± 0.51                      2.12 ± 0.63     
  DP cells (×10^6^)                  49.3 ± 6.4                       31.0 ± 6.9      
  CD4^+^ SP cells (×10^6^)           5.66 ± 1.09                      4.68 ± 0.95     
  CD8^+^ SP cells (×10^6^)           3.46 ± 1.26                      2.37 ± 0.49     
  Ly5.1^+^ DN cells (%)              48.93 ± 6.77    0.11             21.54 ± 6.39    0.05
  Ly5.2^+^ DN cells (%)              27.26 ± 7.37                     55.24 ± 8.51    
  Ly5.1^+^ DP cells (%)              60.36 ± 12.24   0.14             25.28 ± 10.85   0.08
  Ly5.2^+^ DP cells (%)              24.80 ± 10.56                    63.75 ± 11.49   
  Ly5.1^+^ CD4^+^ SP cells (%)       65.47 ± 9.92    0.08             26.22 ± 10.13   0.08
  Ly5.2^+^ CD4^+^ SP cells (%)       27.34 ± 9.31                     64.46 ± 10.33   
  Ly5.1^+^ CD8^+^ SP cells (%)       54.04 ± 10.81   0.33             17.74 ± 8.23    0.02
  Ly5.2^+^ CD8^+^ SP cells (%)       36.31 ± 9.87                     70.23 ± 10.26   
  **Blood**                                                                           
  Cells (/µl)                        10,755 ± 895                     10,391 ± 799    
  Monocytes (/µl)                    616 ± 78                         422 ± 62        
  Granulocytes (/µl)                 970 ± 111                        685 ± 99        
  B220^+^IgM^−^ B cells (/µl)        3,821 ± 822                      3,562 ± 560     
  IgM^+^ B cells (/µl)               1,845 ± 437                      2,188 ± 502     
  CD4^+^ T cells (/µl)               1,803 ± 178                      1,746 ± 135     
  CD8^+^ T cells (/µl)               1,073 ± 103                      1,006 ± 77      
  Ly5.1^+^ monocytes (%)             46.34 ± 8.69    0.65             27.44 ± 9.23    0.11
  Ly5.2^+^ monocytes (%)             38.05 ± 8.96                     60.49 ± 9.36    
  Ly5.1^+^ granulocytes (%)          45.74 ± 6.60    0.39             29.14 ± 8.58    0.18
  Ly5.2^+^ granulocytes (%)          38.28 ± 7.59                     56.30 ± 9.90    
  Ly5.1^+^ B220^+^IgM^−^ cells (%)   45.24 ± 5.19    0.88             21.64 ± 8.10    0.03
  Ly5.2^+^ B220^+^IgM^−^ cells (%)   38.42 ± 6.10                     66.00 ± 8.74    
  Ly5.1^+^ B220^+^IgM^+^ cells (%)   38.33 ± 4.94    0.96             18.24 ± 7.46    0.02
  Ly5.2^+^ B220^+^IgM^+^ cells (%)   34.51 ± 5.38                     60.74 ± 8.12    
  Ly5.1^+^ CD4^+^ cells (%)          56.86 ± 4.88    0.02             29.47 ± 8.29    0.18
  Ly5.2^+^ CD4^+^ cells (%)          23.67 ± 4.84                     49.59 ± 8.13    
  Ly5.1^+^ CD8^+^ cells (%)          45.71 ± 3.43    0.01             23.69 ± 5.43    0.11
  Ly5.2^+^ CD8^+^ cells (%)          19.22 ± 3.14                     37.96 ± 5.71    

The transplantation procedure and groups are defined in [Fig. 5 D](#fig5){ref-type="fig"}. Values represent means of *n* = 10--11 animals of three independent experiments ± SEM. Significant p-values with regard to the Ly5.1^+^/Ly5.2^+^ ratio are indicated (Wilcoxon test). DN, double negative; DP, double positive; SP, single positive.

Uptake of TAT--BCL-XL by human CD34^+^ cells results in protection from apoptosis in vitro {#s09}
------------------------------------------------------------------------------------------

We have previously shown that the proapoptotic functions of BIM and BMF during transplantation-associated apoptosis are conserved between mouse and human HSPCs ([@bib32]). Because of our encouraging results with mouse LSK cells, we reached out to extend the protein transduction approach to human cord blood--derived CD34^+^ cells. To this aim, we generated a human BCL-XL protein coupled to the TAT sequence (TAT--BCL-XL). 2-h incubation of human cord blood--derived CD34^+^ cells with TAT--BCL-XL resulted in inefficient protein uptake ([Fig. 6 A](#fig6){ref-type="fig"}). Efficiency of protein uptake could not be increased by using higher protein concentrations (up to 6 µM), optimized media conditions, longer incubation periods, or repeated addition of recombinant protein to the cells as performed by [@bib30] for TAT-HOXB4 (not depicted). Neither replacing dextran sulfate with methyl-β-cyclodextrin, known to deplete cholesterol from the cell surface, nor using a combination thereof at different temperatures (4°C, 30°C, and 37°C) to allow for different ways of protein uptake (membrane diffusion vs. endocytosis) improved uptake efficiency. Moreover, the use of a Chariot reagent to stimulate protein uptake in a TAT-independent way was also unsatisfactory. However, the few CD34^+^ cells that were successfully transduced with TAT--BCL-XL were efficiently protected from cytokine deprivation--induced apoptosis as reflected by their strong accumulation ([Fig. 6 B](#fig6){ref-type="fig"}) and the reduced rate of specific apoptosis over 6 d of culture ([Fig. 6 C](#fig6){ref-type="fig"}). In summary, TAT--BCL-XL protein transduction can be used to increase the viability of human CD34^+^ cells subjected to stress stimuli usually occurring during the period of transplantation and early engraftment.

![**Human TAT--BCL-XL protein protects human CD34^+^ cells under conditions of stress.** (A) Fresh cord blood derived CD34^+^ cells were treated with dextran sulfate (100 μg/ml) for 30 min and TAT--BCL-XL (1.5 μM) for 2 h in serum-free medium. At day 2, TAT--BCL-XL--positive cells were determined by intracellular flow cytometry using an anti--BCL-XL antibody. (B) TAT--BCL-XL--treated or untreated CD34^+^ cells were cultured in the presence or absence of rhSCF, rhFlt3L (100 ng/ml each), rhTPO (50 ng/ml), and rhIL3 (20 ng/ml) for 6 d. At days 2, 4, and 6, percentage of TAT--BCL-XL--positive cells was determined by flow cytometry. Bars represent x-fold accumulation = (%TAT--BCL-XL^+^ in absence of cytokines)/(%TAT--BCL-XL^+^ cultured with cytokines). (C) At days 2, 4, and 6, apoptosis was determined in the different cell populations (untreated, TAT--BCL-XL--negative, and TAT--BCL-XL--positive cells) by flow cytometry, and the percent specific apoptosis was determined. Bars represent means of *n* = 5 from four independent experiments ± SEM. Significant p-values (Mann--Whitney test): (C) P = 0.02 for TAT--BCL-XL negative vs. TAT--BCL-XL positive on day 4; P = 0.04 for untreated vs. TAT--BCL-XL positive and TAT--BCL-XL negative vs. TAT--BCL-XL positive.](JEM_20161721_Fig6){#fig6}

Discussion {#s10}
==========

Inhibition of the proapoptotic proteins BIM and BMF strongly improved performance of mouse and human HSPCs during transplantation ([@bib32]), but this was associated with an increased risk of malignant transformation and autoimmunity in recipient mice ([@bib33]). Thus, inhibiting apoptosis transiently during the stressful period of transplantation (from HSPC isolation to homing and resumption of hematopoiesis) might be an attractive strategy to improve HSCT outcome without increasing the risk of long-term adverse effects.

Apoptosis of HSPCs could be inhibited at different levels. Stimulation with the cytokines SCF and Flt3L increases cell viability at least partially by inhibiting *Bim* and *Bmf* mRNA expression ([@bib32]), but these cytokines promote proliferation and differentiation at the expense of self-renewing LT-HSCs. Inhibition of caspases, the executioners of apoptosis, appears to be a straightforward approach, but our experiments revealed that using a pan-caspase inhibitor before transplantation does not improve transplantation outcome. One shortcoming of caspase inhibition is that it cannot prevent mitochondrial damage and loss of function, which can cause cell death even in the absence of active caspases ([@bib56]). We are thus convinced that the most promising approach to transient apoptosis inhibition in HSPCs is to manipulate the equilibrium between pro- and antiapoptotic Bcl-2 family members, the "integration device" that controls survival--death decisions upstream of mitochondria. Increasing the amount of antiapoptotic BCL-XL is particularly attractive, because it antagonizes BIM and BMF, as well as BAK and BAX, thereby stabilizing mitochondrial integrity. One major advantage of this approach is that a plethora of different stress signals converge at the level of the BCL-2 family. Higher BCL-XL levels thus can be protective, even if upstream signals and pathways have not been fully characterized. Although it can be anticipated that loss of niche signals are responsible for apoptosis, the specific proteins and signaling pathways involved in transplantation-induced apoptosis have only been partially identified (e.g., cytokine deprivation; [@bib41]; [@bib51]; [@bib20]; [@bib7]).

Here, we achieved transient apoptosis inhibition through BCL-XL overexpression by either adenoviral vectors or ex vivo transduction of recombinant protein. Both methods resulted in the protection of mouse LSK cells from cytokine-induced apoptosis in vitro (6--8 d) and conferred promising in vivo advantages in transplantation experiments, which were detected as soon as 10 d after transplantation and remained stable over time. 16 wk after transplantation, most hematological cells were still derived from those LSK cells that intermittently had overexpressed BCL-XL, indicating a successful manipulation of LT-HSCs, the cells that are required for lifelong hematopoiesis. Whereas the method of adenoviral infection itself resulted in toxicity and thus poor engraftment of mouse LSK cells, the protein transduction approach appeared superior. Although full-length BCL-XL showed strong antiapoptotic activity, its isolated BH4 domain did not inhibit LSK cell apoptosis. This observation contrasts those of earlier studies ([@bib50]; [@bib28]; [@bib26]; [@bib15]) but is corroborated by recent work showing that the BH4 domain is primarily involved in Ca^2+^ signaling ([@bib40]).

A key question concerning clinical applicability is whether transient apoptosis inhibition in donor cells is harmful to the recipient by paving the way for leukemia. Conceptually, short-term apoptosis resistance should keep HSPCs alive during the time of inadequate supply with prosurvival signals but not suffice to promote transformation. Seriously damaged donor cells or cells carrying aberrantly activated oncogenic signaling should undergo apoptosis upon sufficient decline of exogenous BCL-XL levels. Along this line, short-term resistance to apoptosis did not cause or accelerate malignant transformation on either a WT or premalignant background. One potential threat could emerge from possible rare integration or recombination events of adenoviruses. Although we could not detect evidence of viral integration or permanent BCL-XL overexpression, such a risk cannot be entirely ruled out. In contrast, protein transduction of BCL-XL does not involve genetic material and is thus not associated with a similar risk.

To analyze the immediate translational potential of our work, we applied the protein transduction protocol to human cord blood--derived CD34^+^ cells. Although protein uptake by CD34^+^ cells was rather poor, TAT--BCL-XL robustly protected CD34^+^ cells from cytokine deprivation--induced apoptosis for up to 6 d. In the longer term, the exchange of the CPP or the use of "sneaking ligands" specific for human CD34 could be envisioned to optimize protein transduction ([@bib47]; [@bib46]). Nevertheless, direct inhibition of BIM and BMF or BAX and BAK by small-molecule drugs might be a superior strategy. As specific BAX/BAK inhibitors are currently under development, the need for efficient protein uptake in human HSPCs might soon be dispensable.

In sum, we show that transient apoptosis inhibition for 6--8 d during the engraftment period is sufficient to positively influence hematopoietic engraftment of donor HSPCs without increasing the risk of malignant transformation. Considering the relevance of HSCT for many hematological, immunological, and malignant diseases, our contribution is of high value, especially for patients who do not yet have access to HSCT because of the lack of a suitable donor ([@bib38]). In particular, our approach could secure increased access of adult patients to UCB transplantation and improve graft quality in case of long transport routes or when cell separation is required before infusion (e.g., blood group incompatibility). Other possible fields of application would be HSCT after reduced-intensity conditioning or haploidentical transplantation, two situations in which donor stem cells are strongly challenged and require special fitness to survive the hostile environment ([@bib21]; [@bib2]). Generally, our approach will be beneficial for all patients undergoing HSCT. Transplantation of particularly fit and stress-resistant donor HSPCs will minimize the risk of graft failure and accelerate hematopoietic regeneration, thus reducing transplantation-associated morbidity and mortality caused by infections and bleeding.

Our approach to transient apoptosis inhibition has the potential to be used for other forms of cell therapy. Granulocyte transfusions are strongly restricted by the very short half-life of granulocytes (7--8 h). It has been shown that overexpression of antiapoptotic BCL-2 protein results in prolonged granulocyte survival ([@bib52]). Similarly, transfused platelets have a half-life of hours to days and undergo apoptosis in a BAK-dependent manner that is inhibited by BCL-XL. The required transfusion frequency for granulocytes or platelets might therefore be strongly reduced by BCL-XL transduction or BAX/BAK inhibition. In all of these settings, donor cells can be manipulated ex vivo, and no additional in vivo treatment of the donor and/or recipient is required, thus preventing systemic side effects. Over the long run, our approach to transient apoptosis inhibition could also be used to prevent myelosuppression during chemotherapy against solid cancers. In such a scenario, antiapoptotic substances must be delivered strictly and exclusively to BM CD34^+^ cells, and their uptake by cancer cells must be prevented by all means. It can be expected that novel achievements of targeted drug delivery will eventually enable such an application.

Materials and methods {#s11}
=====================

Mice {#s12}
----

C57BL/6 WT (Ly5.2), B6.SJL-*Ptprc*^a^*Pepc*^b^/BoyJ (Ly5.1), Ly5.1/Ly5.2 heterozygous, and C57BL/6-*Rag1^−/−^* mice ([@bib39]) were used for transplantation experiments. In addition, B6.Cg-Tg(IghMyc)22Bri/J (Eμ-*MYC* tg) mice were used ([@bib22]). All recipient mice were kept under specific pathogen--free conditions and received enrofloxacin for transplantation (−1 wk to +4 wk). All experiments were performed according to the guidelines of German laws regarding animal experiments and approved by local committees (RP Freiburg/Germany).

Cell isolation and culture {#s13}
--------------------------

Mouse LSK cells were isolated by magnetic bead depletion of lineage marker--positive cells (MACS lineage cell depletion kit containing antibodies for CD5, B220, CD11b, Gr-1, 7--4, and Ter-119; Miltenyi) and subsequent sorting of viable (7-AAD--negative) sca-1^+^c-kit^+^ cells using a MoFlo Astrios sorter (Beckman Coulter). LSK cells were cultured in IMDM (PAA) supplemented with 0.5 mg/ml penicillin and 0.5 mg/ml streptomycin (Sigma), 10% FCS (PAA), and the recombinant mouse cytokines SCF, TPO, and Flt3L (100 ng/ml each; Immunotools). Where indicated, cells were cultured in the absence of cytokines or treated with 1 µg/ml etoposide (Sigma-Aldrich), 30 µg/ml Taxol (Sigma-Aldrich), 50 µM Q-VD-OPh (MP Biomedicals), and/or 50 µM Nec1 (Merck).

Human UCB was obtained immediately after caesarean birth. Informed consent was given by the parents and approval by the local ethics committee. After density gradient centrifugation, CD34^+^ cells were enriched by magnetic beads. Purity of cells was evaluated by flow cytometry and generally \>90%. Isolated cells were cultured in serum-free medium supplemented with ES-FBS (Invitrogen) and the human cytokines SCF and FLT3L (100 ng/ml each), 50 ng/ml TPO, and 20 ng/ml IL-3 (Immunotools or Preprotech). Cells were cultured at a density of 10^5^--10^6^/ml. Alternatively, purified cells were frozen in serum/10% DMSO, stored in liquid nitrogen, and used at later time points.

Adenoviral vectors {#s14}
------------------

Recombinant plasmids were generated using Gateway cloning technology (Invitrogen) based on the pAd/CMV/V5-DEST vector (Invitrogen). Because of deletions in the E1 and E3 genes, the viruses were replication incompetent. For adenoviral generation and amplification, a protocol from [@bib34] was adapted. In brief, HEK293A cells were transfected at a confluence of ∼50--70% using the ProFection Mammalian Transfection System (Promega) according to manufacturer's recommendations. When cell lysis became evident, cells were scraped off and viral release was promoted by four freeze--thaw--vortex cycles. Viruses were stepwise amplified three more times by adding the viral supernatant to increasing HEK293A cell numbers. Viral supernatant was purified using the Vivapure AdenoPACK kit (Sartorius) according to manufacturer's recommendations. For transduction, LSK cells and viruses were coincubated at 37°C for 4 h at a multiplicity of infection of 10 in medium. Venus and BCL-XL overexpression was confirmed by Western blotting or flow cytometry. Adenoviral work was approved by the local committees (RP Tübingen/Germany) and performed under S2 safety conditions.

TAT-BH4 peptide and TAT--Bcl-xL protein {#s15}
---------------------------------------

TAT-BH4 was purchased from Merck or Genaxxon, and FITC-TAT-BH4 was obtained from Genaxxon. The plasmid expressing TAT--Bcl-xL was cloned into the pTAT-HA vector (generated by S. Dowdy) by G. Dietz, who made it available for this study ([@bib14]). Human TAT--BCL-XL was also cloned into the pTAT-HA vector generated by S. Dowdy. The expression cassette also included a sequence encoding six histidine residues and an HA sequence. Expression and purification of mouse TAT--Bcl-xL and human TAT--BCL-XL was performed as described previously ([@bib13]). In brief, BL21(DE3)-RIPL *Escherichia coli* were transformed with pTAT--Bcl-xL and amplified in ampicillin- and chloramphenicol-containing LB media, and protein expression was induced by thiogalactopyranoside. Proteins were extracted using an EmulsiFlex-C5 (Avestin). The supernatant was subjected to metal-affinity chromatography using Ni-NTA (Qiagen). For salt/denaturant removal and buffer exchange, affinity-purified proteins were added to PD-10 columns (GE Healthcare Life Sciences) and eluted with a buffer containing 10 mM Tris, pH 10, 0.1 mM EDTA, 15% glycerol, 0.1% pluronic acid, and 0.02% Tween-80. The identity of the protein was confirmed by Western blotting.

To facilitate peptide or protein transduction, mouse LSK cells or human CD34^+^ cells cultured in whole medium were first treated with 100 µg/ml dextran sulfate for 30 min and subsequently incubated with 500--2,000 nM TAT-BH4 for 12 h or 1.5 µM TAT--Bcl-xL for 2 h. To increase protein uptake in human CD34^+^ cells, cells were also treated with 5 mM methyl--β-cyclodextrin (Sigma) for 30 min, with or without dextran sulfate. In addition, we analyzed the influence of different temperatures (4°C, 30°C, and 37°C) on protein transduction efficiency ([@bib19]). The Chariot reagent (Active Motif) was used according to the manufacturer's protocol with β-galactosidase as positive control. In addition, we used the protocol of repeated protein transduction reported by [@bib30].

Transplantation assays {#s16}
----------------------

For competitive reconstitution assays, 30,000 adenovirally transduced Ly5.1^+^ LSK cells and 30,000 adenovirally transduced Ly5.2^+^ LSK cells were mixed and transplanted intravenously into Ly5.1/Ly5.2 heterozygous C57BL/6 mice that were lethally irradiated (9.5 Gy) 6--8 h earlier. When *Rag1^−/−^* mice were used as recipients, 20,000 Ly5.1^+^ and 20,000 Ly5.2^+^ cells were used for transplantation. When TAT--Bcl-xL protein transduction was used to influence transplantation outcome, 20,000 Ly5.1^+^ and 20,000 Ly5.2^+^ LSK cells were used for competitive transplantation. At indicated time points, recipient mice were sacrificed and hematological organs were analyzed by flow cytometry. Another set of Ly5.1^+^ recipient mice was transplanted with 15,000 Ly5.2^+^ LSK cells transduced with Ad5-Venus or Ad5--BCL-XL, together with 200,000 untreated Ly5.1^+^ whole BM cells and analyzed 1 yr after transplantation. BM from these animals was used for serial transplantation, and secondary recipients were analyzed 16 wk later. When Eµ-*MYC* transgenic mice were used as donors, 20,000 differentially treated Eµ-*MYC* tg LSK cells were transplanted, and 200,000 Eµ-myc total BM cells were cotransplanted to ensure mouse survival. Recipient mice were closely monitored for lymphoma development and sacrificed when in poor general condition.

Clonogenicity assay {#s17}
-------------------

Colony-forming assays were performed by plating 300 LSK cells on a semisolid medium containing insulin, transferrin, rmSCF, rmIL-3, rhIL-6, and rhEPO (GF M3434; MethoCult). After incubating cells for 7 d at 37°C, the different colony types were quantified by light microscopy based on typical morphological features.

Flow cytometric analysis {#s18}
------------------------

Single-cell suspensions of hematopoietic organs were surface stained with monoclonal antibodies conjugated with FITC, PE, APC, PE-Cy7, or biotin. The antibodies used for mouse cell-surface markers were anti-CD11b (M1/70), anti--Ly-6G/Ly-6C (RB6-8C5), anti--CD45R/B220 (RA3-6B2), anti-IgM (RMM-1), anti-CD4 (RM4-5), anti-CD8a (53--6.7), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD117 (2B8/3C11), anti--Ly-6A/E (D7/E13-161.7), anti--TER-119 (TER119), anti-CD44 (IM7), and anti-CD25 (PC61); all were purchased from eBioscience or BioLegend. The lineage cocktail (eBioscience) contained the following antibodies: anti-CD11b (Mac-1) M1/70, anti--CD3e 145-2C11, anti--CD45R (B220) RA3-6B2, anti--Ly6G (Gr-1) RB6-8C5, anti--TER-119 Ly-76, and anti--Nk1.1 PK136. Antibodies for human cell surface markers were anti-CD45 (HI30 and 30-F11) and anti-CD34 (AC136). For mouse TAT--Bcl-xL and human TAT--BCL-XL detection by intracellular flow cytometry, cells were fixed using 4% paraformaldehyde, permeabilized with PBS/0.5% saponin, and stained with anti--Bcl-xL (H-5) mouse mAb (Santa Cruz Biotechnology) in PBS/0.5% saponin for 30 min. Biotinylated antibodies were detected using streptavidin coupled to PE or PE-Cy7. Apoptosis was determined by 7-AAD/Annexin-V stain or the Nicoletti stain (sub-G0) using 7-AAD or DAPI. Flow cytometric analysis was performed using a FACScalibur or a Canto II (BD). Specific apoptosis triggered by cytokine withdrawal or etoposide was calculated by the following equation: (induced apoptosis − spontaneous apoptosis) / (100 − spontaneous apoptosis).

Immunoblotting {#s19}
--------------

Proteins were purified and size fractioned by 12% SDS-PAGE under reducing conditions and transferred onto nitrocellulose membranes by electroblotting. For detection of TAT--Bcl-xL, either anti--Bcl-x (44/Bcl-x) mouse mAb (BD Bioscience) or anti--HA-Tag (C29F4) rabbit mAb (Cell Signaling Technology) was used. As a positive control for BCL-XL overexpression, the Burkitt lymphoma cell line BL40 was used. Secondary reagents were conjugated to peroxidase, and signal was detected by enhanced chemiluminescence. Fractionated Western blotting was performed by using the Mitochondria Isolation kit for Cultured Cells (Thermo Fisher Scientific) according to manufacturer's recommendations.

Immunofluorescence {#s20}
------------------

For fluorescence microscopy, LSK cells were cultured in eight-well µ-Slides (Ibidi), treated with 100 µg/ml dextran sulfate for 30 min, and washed twice with serum-free medium. 1.5 µM Alexa Fluor 488--labeled TAT--Bcl-xL was added for 2 h in serum-free medium. After washing, fresh medium with serum supplemented with 1 µM MitoTracker red and20 nM Hoechst was added for 15 min. Cells were kept in phenol red--free DMEM at 37°C and 5% CO~2~ for imaging using a Zeiss LSM 710 microscope.

Statistical analysis {#s21}
--------------------

Statistical analysis was performed using the Mann--Whitney Test (unpaired) or the Wilcoxon test (paired). For survival analysis, the log-rank test (Mantel--Cox test) and Statview 4.1 were used. P-values \<0.05 were considered statistically significant. In the figures: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.

Online supplemental material {#s22}
----------------------------

Fig. S1 shows the gating strategy used for analysis of recipient mice. Fig. S2 shows the competitive reconstitution assays using LSK cells infected with adenoviruses. Fig. S3 depicts the in vitro and in vivo experiments using LSK cells treated with Q-VD-OPh and/or Nec1. Fig. S4 depicts the in vitro experiments using LSK cells treated with TAT-BH4. Fig. S5 shows localization and degradation of TAT--BCL-XL protein in HeLa cells.
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